Molecular biomarkers have become indispensable tools not only for the diagnosis and stratification of patients with neurodegenerative diseases such as Alzheimer’s disease (AD), but also for monitoring disease progression or treatment response. However, despite remarkable advances in detectability of liquid biomarkers in recent years, the interpretation of protein changes in patients’ CSF and blood is often limited since underlying cellular mechanisms in the brain are largely inaccessible.
